These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 25539158

  • 1. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
    Pontillo D, Patruno N.
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):142. PubMed ID: 25539158
    [No Abstract] [Full Text] [Related]

  • 2. Increased risk of myocardial infarction with dabigatran: fact or fiction?
    Giglio AF, Basile E, Santangeli P, Di Biase L, Trotta F, Natale A.
    J Cardiovasc Med (Hagerstown); 2014 Jan; 15(1):19-26. PubMed ID: 24492353
    [Abstract] [Full Text] [Related]

  • 3. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
    Clemens A, Fraessdorf M, Friedman J.
    Vasc Health Risk Manag; 2013 Jul; 9():599-615. PubMed ID: 24143109
    [Abstract] [Full Text] [Related]

  • 5. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
    Zotova IV, Zateĭshchikov DA.
    Kardiologiia; 2014 Jul; 54(2):79-85. PubMed ID: 24888206
    [No Abstract] [Full Text] [Related]

  • 6. Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
    Pollack CV, Levy JH, Eikelboom J, Weitz JI, Sellke FW, Huisman MV, Steiner T, Kamphuisen P, Bernstein RA.
    Am J Emerg Med; 2014 Nov; 32(11):1433-4. PubMed ID: 25239691
    [No Abstract] [Full Text] [Related]

  • 7. Dabigatran-induced acute hepatitis.
    Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A.
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):549-50. PubMed ID: 22962308
    [No Abstract] [Full Text] [Related]

  • 8. The importance of postapproval data for dabigatran.
    Redberg RF.
    JAMA Intern Med; 2015 Jan; 175(1):25. PubMed ID: 25365377
    [No Abstract] [Full Text] [Related]

  • 9. Dabigatran and myocardial infarction: a foggy scenario.
    Pontillo D, Patruno N.
    Vasc Health Risk Manag; 2014 Jan; 10():45-8. PubMed ID: 24476689
    [No Abstract] [Full Text] [Related]

  • 10. Dabigatran for stroke prevention in atrial fibrillation.
    Hohnloser SH, Diener HC.
    Hamostaseologie; 2012 Jan; 32(3):216-20. PubMed ID: 22739760
    [Abstract] [Full Text] [Related]

  • 11. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Hirano T.
    Circ J; 2014 Jan; 78(6):1317-9. PubMed ID: 24805358
    [No Abstract] [Full Text] [Related]

  • 12. Place of dabigatran in contemporary pharmacotherapy.
    Gums JG.
    Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
    [No Abstract] [Full Text] [Related]

  • 13. Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".
    Jacobs JM, Stessman J.
    Arch Intern Med; 2012 Mar 12; 172(5):403-4. PubMed ID: 22231616
    [No Abstract] [Full Text] [Related]

  • 14. [Advantages of NOAKs validated in clinical routine].
    Ameri AA.
    MMW Fortschr Med; 2015 May 13; 157(9):70. PubMed ID: 26012835
    [No Abstract] [Full Text] [Related]

  • 15. Dabigatran: patient management in specific clinical settings.
    Kyrle PA, Binder K, Eichinger S, Függer R, Gollackner B, Hiesmayr JM, Huber K, Lang W, Perger P, Quehenberger P, Roithinger FX, Schmaldienst S, Weltermann A, Domanovits H.
    Wien Klin Wochenschr; 2014 Sep 13; 126(17-18):503-8. PubMed ID: 25138549
    [Abstract] [Full Text] [Related]

  • 16. Dabigatran and myocardial infarction: meta-illusion?
    Correia LC, Lopes AA.
    Arch Intern Med; 2012 May 28; 172(10):823; author reply 823. PubMed ID: 22636828
    [No Abstract] [Full Text] [Related]

  • 17. [Dabigatran and risk of bleeding].
    Hasler S.
    Praxis (Bern 1994); 2015 Jan 28; 104(3):157-8. PubMed ID: 25626386
    [No Abstract] [Full Text] [Related]

  • 18. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF.
    Nat Rev Nephrol; 2015 Jan 28; 11(1):3. PubMed ID: 25421829
    [No Abstract] [Full Text] [Related]

  • 19. Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.
    Heart Advis; 2011 Jan 28; 14(1):4. PubMed ID: 22973590
    [No Abstract] [Full Text] [Related]

  • 20. [Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
    Molinier A, Acket B, Bourrel R, Lavezzi O, Montastruc JL, Bagheri H.
    Presse Med; 2014 Apr 28; 43(4 Pt 1):468-9. PubMed ID: 24534477
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.